Prior Agenda
(Oncology - June 2023)
WEDNESDAY, JUNE 21, 2023
All Times are EST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // KEYNOTE TALK - Dr. Raju Kucherlapati, Co-Founder Millennium Pharmaceutical (now Takeda Oncology) / Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School. Topic: Changing Landscape of Cancer Drug Development
9:40am // Corporate Presentation - Picture Health
10:00am // Corporate Presentation - Thrive Bioscience
10:20am // Corporate Presentation - Antion Biosciences
10:40am // Corporate Presentation - Levatio Therapeutics
11:00am // Corporate Presentation - Oncolize
11:20am // Corporate Presentation - TibaRay
11:40am // Corporate Presentation - Rapa Therapeutics
12:00pm // Processa Pharmaceuticals (NasdaqCM: PCSA)
12:20pm // NeoTx
12:40pm // LUNCH BREAK - PANEL DISCUSSION
12:50pm // ONCOLOGY INVESTOR PANEL DISCUSSION: Moderator: William Werkmeister, HRN. Panelists: Chistiana Bardon, Co-Managing Partner MPM Oncology Impact Fund | Dr. Brian Yordy, Principal, F-Prime Capital | Rakhshita Dhar, Senior Director Venture Investments, LEAPS by Bayer | Ben Freeberg, Managing Partner, Oncology Ventures
1:30pm // CEO WORKSHOP: Achieving Commercial Success with the NIH as a Strategic Partner. Curators: Dr. Michael Salgaller, Director of Tech Transfer, NCI | Supervisor, Invention Development and Marketing Unit (IDMU); Steve Ferguson, Deputy Director, Licensing and Entrepreneurship, National Institutes of Health
2:20pm // Corporate Presentation - PAZ Pharmaceuticals
2:40pm // Corporate Presentation - Canget BioTekpharma
3:00pm // Corporate Presentation - Lumicell
3:20pm // Corporate Presentation - Perthera
3:40pm // Corporate Presentation - Osmol Therapeutics
4:00pm // Corporate Presentation - Blue Note Therapeutics
4:20pm // Corporate Presentation - CyGenica
4:40pm // Corporate Presentation - LabyRx Immuno-Oncology
5:00pm // Corporate Presentation - Rakovina Therapeutics
5:20pm // Corporate Presentation - Kiyatech
5:40pm // Corporate Presentation - SciTech Development
6:00pm // Corporate Presentation - Jaguar Health (NasdaqCM: JAGX)
6:20pm // SPEAKERS - Yasin Akbari, Partner & Stephanie Richards, Partner, Goodwin Law Firm. Topic: Strategies for Raising Capital in the Current Market Environment
6:50pm // CLOSING REMARKS
7:00pm // RECEPTION
THURSDAY, JUNE 22, 2023
All Times are EST Time Zone
8:30am // REGISTRATION AND BREAKFAST
9:00am // OPENING REMARKS
9:10am // SPEAKERS - Michael Salgaller, Director of Tech Transfer, NCI | Supervisor, Invention Development and Marketing Unit (IDMU); Steve Ferguson, Deputy Director, Licensing and Entrepreneurship, National Institutes of Health. Topic: Working with the NIH to Improve Pipe-Lines and Bottom-Lines
9:50am // Corporate Presentation - Geneius Biotechnology
10:10am // Corporate Presentation - Lifebridge 10000
10:30am // Corporate Presentation - Xipiro
10:50am // Corporate Presentation - MetriTrack
11:10am // Corporate Presentation - Cantex Pharmaceuticals
11:30am // Corporate Presentation - Bexion Pharmaceuticals
11:50am // Corporate Presentation - CellVax Therapeutics
12:10pm // Corporate Presentation - Boston Immune Technologies and Therapeutics
12:30pm // Corporate Presentation - Pleco Therapeutics
12:50pm // LUNCH BREAK - GOODWIN TALK
1:00pm // SPEAKERS - Alex Varond, Partner and Steven Tjoe, Partner, Goodwin Law Firm. Topic: Key Regulatory Considerations for Oncology Companies in 2023
1:30pm // Corporate Presentation - Adiposs
1:50pm // Corporate Presentation - TATUM Bioscience
2:10pm // Corporate Presentation - Therabene
2:30pm // Corporate Presentation - EpiVax Therapeutics
2:50pm // Corporate Presentation - Qu Biologics
3:10pm // Corporate Presentation - Telexos
3:30pm // Corporate Presentation - Coastar Therapeutics
3:50pm // Corporate Presentation - Viska.Bio
4:10pm // Corporate Presentation - Kintara Therapeutics (KTRA)
4:30pm // Corporate Presentation - Starpharma (SPL.AX)
4:50pm // Corporate Presentation - Oncoheroes Biosciences
5:20pm // KEYNOTE TALK - Dr. Alfred Slanetz, Chairman, the National Foundation for Cancer Research, CEO, Geneius Biotechnology, Former CEO, Bluebird Bio Topic: Use of RNA Technology in Cancer Therapeutics
5:50pm // CLOSING REMARKS
6:00pm // RECEPTION